B16 melanoma cells increase B-1 cell survival, IL-10 production and radioresistance in vitro

Immunobiology

Volumn 218, Issue 4, 2013, Pages 609-619

  Laurindo, Maria Fernanda Lucatelli ^a   Thies, Felipe Garutti ^a   Perez, Elizabeth Cristina ^a,b   Novaes e Brito, Ronni Rômulo ^a   Mariano, Mario ^a,b   Popi, Ana Flavia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b PAULISTA UNIVERSITY   (Brazil)

Author keywords

B 1 cells; B16 cells; IL 10; Radioresistance

Indexed keywords

INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CELL DEATH; CELL DIFFERENTIATION; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CELL VIABILITY; IN VITRO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PERITONEAL CAVITY; PHENOTYPE; PLEURA CAVITY; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANIMALS; B-LYMPHOCYTE SUBSETS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; INTERLEUKIN-10; MELANOMA; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; PERITONEUM; PLEURAL CAVITY;

EID: 84875249639     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.032     Document Type: Article

References (46)

1. Alas S., Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001, 61(13):5137-5144.
2. Almeida S.R., et al. Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int. Immunol. 2001, 13(9):1193-1201.
3. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545.
4. Benkhart E.M., et al. Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression. J. Immunol. 2000, 165(3):1612-1617.
5. Bennett D.C., Cooper P.J., Hart I.R. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 1987, 39(3):414-418.
6. Borrello M.A., Phipps R.P. Fibroblasts support outgrowth of splenocytes simultaneously expressing B lymphocyte and macrophage characteristics. J. Immunol. 1995, 155(9):4155-4161.
7. Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55(20):4633-4639.
8. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7(5):411-423.
9. Disis M.L., Lyerly H.K. Global role of the immune system in identifying cancer initiation and limiting disease progression. J. Clin. Oncol. 2005, 23(35):8923-8925.
10. Fiorentino D.F., et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991, 146(10):3444-3451.
11. Ghosn E.E., et al. CD11b expression distinguishes sequential stages of peritoneal B-1 development. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(13):5195-5200.
12. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3(1):23-35.
13. Gu Z.J., et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996, 88(10):3972-3986.
14. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
15. Hayakawa K., et al. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med. 1983, 157(1):202-218.
16. Herzenberg L.A., et al. The Ly-1 B cell lineage. Immunol. Rev. 1986, 93:81-102.
17. Inoue S., et al. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006, 66(15):7741-7747.
18. Ishida H., et al. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J. Exp. Med. 1992, 175(5):1213-1220.
19. Kantor A.B., Herzenberg L.A. Origin of murine B cell lineages. Annu. Rev. Immunol. 1993, 11:501-538.
20. Karras J.G., et al. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J. Exp. Med. 1997, 185(6):1035-1042.
21. Koide N., et al. Change of mouse CD5(+) B1 cells to a macrophage-like morphology induced by gamma interferon and inhibited by interleukin-4. Clin. Diagn. Lab. Immunol. 2002, 9(6):1169-1174.
22. Li Q., et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J. Immunol. 2009, 183(5):3195-3203.
23. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117(5):1175-1183.
24. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23(11):549-555.
25. Marchi L.H., et al. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-gamma-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther. 2011, 18(2):110-122.
26. Matsuda M., et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 1994, 180(6):2371-2376.
27. Mizutani Y., et al. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J. Urol. 1994, 151(6):1697-1702.
28. Nemunaitis J., et al. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001, 19(3):239-247.
29. O'Garra A., et al. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 1992, 22(3):711-717.
30. Oliveira H.C., et al. B-1 cells modulate the kinetics of wound-healing process in mice. Immunobiology 2010, 215(3):215-222.
31. Otero D.C., et al. Cutting edge: inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3. J. Immunol. 2006, 177(10):6593-6597.
32. Perez E.C., et al. B-1 lymphocytes increase metastatic behavior of melanoma cells through the extracellular signal-regulated kinase pathway. Cancer Sci. 2008, 99(5):920-928.
33. Petersson M., et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol. 1998, 161(5):2099-2105.
34. Popi A.F., Lopes J.D., Mariano M. Interleukin-10 secreted by B-1 cells modulates the phagocytic activity of murine macrophages in vitro. Immunology 2004, 113(3):348-354.
35. Popi A.F., et al. Co-ordinated expression of lymphoid and myeloid specific transcription factors during B-1b cell differentiation into mononuclear phagocytes in vitro. Immunology 2009, 126(1):114-122.
36. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10(3):170-181.
37. Sato T., et al. Interleukin 10 production by human melanoma. Clin. Cancer Res. 1996, 2(8):1383-1390.
38. Shah S., et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 2005, 117(4):574-586.
39. Sredni B., et al. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 2004, 64(5):1843-1852.
40. Staquicini F.I., et al. Enzyme and integrin expression by high and low metastatic melanoma cell lines. Melanoma Res. 2003, 13(1):11-18.
41. Staquicini F.I., et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008, 68(20):8419-8428.
42. Stassi G., et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 63(20):6784-6790.
43. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117(5):1137-1146.
44. Wong S.C., et al. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol. 2010, 40(8):2296-2307.
45. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7(1):41-51.
46. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6(4):295-307.